Hong Kong, July 11, 2014 - (ACN Newswire) - On 3 July 2014, Southern Weekly announced the results of "2014 Survey on CSR of China's Listed Pharmaceutical & Food Companies". Fosun Pharma (Stock code: 1260.HK), with a total score of 79.55, ranked first in the List of Survey on Corporate Social Responsibility of China's Listed Pharmaceutical Companies. As noted, the "2014 Survey on CSR of China's Listed Pharmaceutical & Food Companies" was held by Southern Weekly from March to June 2014 for a study of China's listed companies in pharmaceutical and food industries. The event aimed to foster consensus over the development of corporate social responsibility of enterprises operating in the health industry and establish indicators and concepts that are generally accepted in the industry. It was also intended to call for joint efforts to promote "corporate social responsibility" and thus turn the vision of the event, i.e. "better health comes from greater responsibility" into reality.
Drawing upon nearly eight years of experience in CSR survey, Southern Weekly took full account of the features of pharmaceutical and food industries and set industry-specific indicators in addition to the standard CSR indicators. These industry-specific indicators focus on whether the manufacture is strictly GMP-compliant, whether a monitoring system is set up for adverse reaction and whether a recall system is established and implemented. These indicators also require enterprises to pass the new HACCP certification and focus on corporate responsibility towards consumers, investors, employees, communities, government and economy and corporate information disclosure responsibility. On such basis, this survey examined the fulfillment of corporate social responsibility of China's listed companies in pharmaceutical and food industries.
Fosun Pharma has upheld the principle of sustainable development and has proactively undertaken its social responsibility. With progress made in terms of economic responsibility, environmental protection, occupational health and safety, staff development and community welfare, the Company met the consolidated CSR performance indicators with remarkable success.
About Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma") was established in 1994. As a leading company in China's pharmaceutical and healthcare industry, Fosun Pharma was listed on the Shanghai Stock Exchange and on the main board of the Hong Kong Stock Exchange(stock code: 600196-SH, 02196-HK) in August 1998 and October 2012. Fosun Pharma strategically operates in several key sectors on the value-chain of the pharmaceutical and healthcare industry. Our main business includes pharmaceutical research and development, manufacturing, distribution and retailing, medical devices and diagnostic products as well as healthcare services. The company owns a national-level Technology Center and has a R&D team with international perspective. We had been continuously focusing on innovative research and development in therapeutic areas such as metabolism and alimentary tract, cardiovascular system, central nervous system, anti-tumor as well as anti-infective treatment .
Our commitment is "Innovation for Good Health". In future, Fosun Pharma will continue to implement its strategy of organic growth with external expansion and integrated business operation. We are dedicated to become a first class enterprise in major global healthcare market. For more information on Fosun Pharma, please visit www.fosunpharma.com
Copyright 2014 ACN Newswire. All rights reserved.
